Last €177.66 EUR
Change Today +2.55 / 1.46%
Volume 171.0
As of 2:59 PM 01/29/15 All times are local (Market data is delayed by at least 15 minutes).

illumina inc (ILU) Snapshot

Open
€173.25
Previous Close
€175.11
Day High
€178.60
Day Low
€169.79
52 Week High
01/28/15 - €186.25
52 Week Low
04/15/14 - €92.00
Market Cap
25.2B
Average Volume 10 Days
259.4
EPS TTM
--
Shares Outstanding
142.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ILLUMINA INC (ILU)

illumina inc (ILU) Details

Illumina, Inc. develops, manufactures, and markets life science tools and integrated systems for the analysis of genetic variation and function in North America, Europe, Latin America, the Asia-Pacific, the Middle East, and South Africa. The company’s products include sequencing platforms that are based on its SBS technology are designed to meet the various demands of a range of sequencing applications; and array platforms consist of HiScan and iScan systems that are array scanners, which support the imaging of array-based genetic analysis products. It also offers various sample preparation and sequencing kits to simplify workflows and accelerate analysis. In addition, the company provides genotyping and whole genome sequencing services. It serves genomic research centers, academic institutions, government laboratories, hospitals, and reference laboratories, as well as pharmaceutical, biotechnology, agrigenomics, commercial molecular diagnostic, and consumer genomics companies. The company sells its products directly, as well as through distributors. It has strategic partnerships with AstraZeneca PLC; Janssen Biotech, Inc.; and Sanofi to focus on the transition from single-analyte companion diagnostics to panel-based assays that select for companion therapeutics. Illumina, Inc. was founded in 1998 and is headquartered in San Diego, California.

Founded in 1998

illumina inc (ILU) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $1.1M
President and Director
Total Annual Compensation: $153.5K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $447.7K
Chief Commercial Officer and Senior Vice Pres...
Total Annual Compensation: $457.1K
Senior Vice President, General Counsel and Se...
Total Annual Compensation: $235.6K
Compensation as of Fiscal Year 2013.

illumina inc (ILU) Key Developments

Illumina Inc. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 28, 2014; Provides Earnings Guidance for the Full Year of Fiscal 2015; Provides Tax Rate Guidance for the First Quarter of 2015

Illumina Inc. announced unaudited consolidated earnings results for the fourth quarter and full year ended December 28, 2014. For the quarter, the company announced total revenue of $512,379,000 compared to $387,326,000 for the same period a year ago. Income from operations was $202,883,000 compared to $73,784,000 for the same period a year ago. Income before income taxes was $192,061,000 compared to $120,369,000 for the same period a year ago. Net income was $153,280,000 compared to $80,661,000 for the same period a year ago. Net income per diluted share was $1.03 compared to $0.56 for the same period a year ago. Net cash provided by operating activities was $140,549,000 compared to $126,839,000 for the same period a year ago. Purchases of property and equipment were $34,832,000 compared to $27,310,000 for the same period a year ago. Free cash flow was $105,717,000 compared to $99,529,000 for the same period a year ago. Non-GAAP net income per share, diluted was $0.87 compared to $0.45 for the same period a year ago. Non-GAAP net income was $128,949,000 compared to $64,504,000 for the same period a year ago. Non-GAAP operating profit was $192,990,000 compared to $124,918,000 for the same period a year ago. Capital expenditures were $35 million, resulting in $106 million of free cash flow. For the full year, the company announced total revenue of $1,861,358,000 compared to $1,421,178,000 for the same period a year ago. Income from operations was $514,711,000 compared to $134,107,000 for the same period a year ago. Income before income taxes was $448,758,000 compared to $159,314,000 for the same period a year ago. Net income was $353,351,000 compared to $125,308,000 for the same period a year ago. Net income per diluted share was $2.37 compared to $0.90 for the same period a year ago. Net cash provided by operating activities was $501,271,000 compared to $386,421,000 for the same period a year ago. Purchases of property and equipment were $105,996,000 compared to $79,215,000 for the same period a year ago. Free cash flow was $395,275,000 compared to $307,206,000 for the same period a year ago. Non-GAAP net income per share, diluted was $2.74 compared to $1.80 for the same period a year ago. Non-GAAP net income was $407,217,000 compared to $249,663,000 for the same period a year ago. Non-GAAP operating profit was $686,275,000 compared to $462,229,000 for the same period a year ago. The company provided earnings guidance for the full year of fiscal 2015. For the fiscal 2015, the company is projecting approximately 20% revenue growth, assuming current currency exchange rates, and non-GAAP earnings per diluted share of $3.12 to $3.18. These projections assume full year non-GAAP gross margin of approximately 73%, and a pro forma tax rate of approximately 28%. The company also expects to report GAAP gross margin of 70.5% and GAAP diluted net income per share between 2.73 and $2.79. The company expects the first quarter of 2015 tax rate of approximately 29%.

Illumina Announces First Targeted Next-Generation Sequencing Solution for Forensic Genomics

Illumina Inc. announced the launch of the MiSeq FGx Forensic Genomics System, the first fully validated forensic next-generation sequencing (NGS) system, which simultaneously interrogates short tandem repeats (STR) and other valuable genetic markers, including single nucleotide polymorphisms (SNPs), to provide informative DNA profiles. The system enables more robust analysis of a broader range of genetic markers in a single workflow than previous technology allowed, supporting the reliable analysis of both routine and challenging forensic DNA samples. With the MiSeq FGx System, crime labs can now identify investigative leads from no suspect cases that may otherwise reach a dead end. Designed in collaboration with forensic genomics and human identification experts, the MiSeq FGx System leverages Illumina's sequencing by synthesis (SBS) chemistry, the most widely adopted NGS technology. Compatible with existing DNA databases, including the Combined DNA Index System (CODIS), the system can be used for criminal casework and in a range of situations, including mass disasters, missing persons, and unidentified human remains. Dense data sets, with powerful population statistics, can be generated for highly compromised samples, such as DNA degraded to less than 100 base pairs, aiding in the identification of the person whose DNA was obtained from the scene of a crime. The technology can also provide SNP-based physical information about bio-geographical ancestry and visible, physical traits, including hair and eye color. This information is often more reliable than eyewitness accounts and can be crucial in cases where traditional investigation does not identify a suspect. In addition to the MiSeq FGx DNA sequencer, the system includes the ForenSeqTM DNA Signature Prep Kit and ForenSeq Universal Analysis Software. This sample-to-answer solution will enable labs to maximize the information derived from a sample, generating more data from a single test than previously possible, and eliminating the need for multiple rounds of partial, iterative testing. Using low quantities of DNA (< 1 ng), the ForenSeq kit amplifies forensic targets via a streamlined workflow that maximizes the genetic information recovered from challenging samples and minimizes the potential for errors. Intuitive ForenSeq software facilitates the complete run setup, sample management, and analysis, and delivers reports on a stand-alone, dedicated server.

Illumina Inc. to Report Q4, 2014 Results on Jan 27, 2015

Illumina Inc. announced that they will report Q4, 2014 results at 5:00 PM, Eastern Standard Time on Jan 27, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ILU:GR €177.66 EUR +2.55

ILU Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Avago Technologies Ltd $106.28 USD +1.28
Becton Dickinson and Co $140.21 USD -0.61
Dr Reddy's Laboratories Ltd 3,363 INR +124.25
Sigma-Aldrich Corp $137.65 USD +0.25
Waters Corp $120.59 USD +1.64
View Industry Companies
 

Industry Analysis

ILU

Industry Average

Valuation ILU Industry Range
Price/Earnings 83.4x
Price/Sales 15.1x
Price/Book 19.3x
Price/Cash Flow 71.5x
TEV/Sales 13.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ILLUMINA INC, please visit www.illumina.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.